Lipocine Financial Statements From 2010 to 2024

LPCN Stock  USD 4.30  0.24  5.29%   
Lipocine financial statements provide useful quarterly and yearly information to potential Lipocine investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lipocine financial statements helps investors assess Lipocine's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lipocine's valuation are summarized below:
Gross Profit
500 K
Profit Margin
(1.77)
Market Capitalization
23 M
Enterprise Value Revenue
0.4004
Revenue
4.8 M
We have found one hundred twenty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipocine's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 3rd of December 2024, Market Cap is likely to drop to about 14 M. In addition to that, Enterprise Value is likely to drop to about 9.5 M

Lipocine Total Revenue

(2.71 Million)

Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Other Operating Expenses of 14.9 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.76 or Book Value Per Share of 3.67. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Lipocine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.7 M23 M25.4 M
Slightly volatile
Other Current Liabilities1.5 M1.2 M1.3 M
Pretty Stable
Total Current Liabilities3.4 M2.6 M2.9 M
Slightly volatile
Other Liabilities196.5 K206.9 K3.3 M
Slightly volatile
Accounts Payable798.8 K1.4 M683.1 K
Slightly volatile
Cash9.2 M4.8 M10.6 M
Pretty Stable
Other AssetsM3.8 MM
Slightly volatile
Cash And Short Term Investments26.6 M22 M22.7 M
Slightly volatile
Common Stock Total Equity10.7 K10.2 KK
Slightly volatile
Common Stock Shares Outstanding5.5 M5.3 M2.2 M
Slightly volatile
Liabilities And Stockholders Equity29.7 M23 M25.4 M
Slightly volatile
Other Current Assets1.5 M773.4 K1.2 M
Slightly volatile
Other Stockholder Equity147.6 M220.1 M126.1 M
Slightly volatile
Total Liabilities5.1 M2.6 M4.4 M
Slightly volatile
Total Current Assets28.8 M22.9 M24.6 M
Slightly volatile
Common Stock9.3 K8.9 K3.9 K
Slightly volatile
Property Plant Equipment124.4 K118.4 K65 K
Pretty Stable
Capital Surpluse143.4 M251 M127.8 M
Slightly volatile
Non Current Assets Total132.9 K139.8 K734 K
Slightly volatile
Property Plant And Equipment Gross1.4 M1.3 M447.2 K
Slightly volatile
Net Receivables49.6 K52.3 K354.2 K
Very volatile
Net Invested Capital27.8 M20.4 M22.5 M
Slightly volatile
Net Working Capital25.5 M20.2 M21.3 M
Slightly volatile
Short and Long Term Debt Total14.7 K15.4 K7.2 M
Slightly volatile
Long Term Debt Total4.3 M3.4 M5.7 M
Slightly volatile
Short and Long Term Debt2.5 M2.1 M3.1 M
Slightly volatile
Capital Stock7.2 K8.9 K4.3 K
Slightly volatile
Short Term Debt14.7 K15.4 K2.6 M
Slightly volatile
Current Deferred Revenue813.2 K914.8 K996.1 K
Slightly volatile
Non Current Liabilities OtherM1.2 M1.3 M
Slightly volatile

Lipocine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.8 M4.9 MM
Slightly volatile
Other Operating Expenses14.9 M15.1 M12.8 M
Slightly volatile
Research Development9.1 M10.2 MM
Slightly volatile
Cost Of Revenue9.4 M10.2 M8.4 M
Slightly volatile
Total Operating Expenses9.3 M15.1 MM
Slightly volatile
Non Recurring582.9 K655.8 K714.1 K
Slightly volatile
Tax Provision411613598
Slightly volatile
Reconciled Depreciation24.4 K23.2 K21.5 K
Slightly volatile
Interest Income1.4 M1.4 M284.7 K
Slightly volatile

Lipocine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow4.5 M4.8 M11.3 M
Pretty Stable
Begin Period Cash FlowM3.1 M11.2 M
Very volatile
Stock Based Compensation1.1 M654.4 K1.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables641.3 K898.4 K757.5 K
Slightly volatile
Capex To Depreciation0.440.45948.1919
Slightly volatile
Payables Turnover157176192
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Cash Per Share3.974.181620.8376
Slightly volatile
Days Payables Outstanding1.491.681.8275
Slightly volatile
Income Quality1.10.72571.3643
Pretty Stable
Current Ratio12.248.687110.7465
Very volatile
Graham Number15.6116.42861.1726
Slightly volatile
Debt To Equity0.05540.05830.767
Slightly volatile
Capex Per Share0.00240.00250.0234
Slightly volatile
Average Receivables590.5 K409.5 K271.4 K
Pretty Stable
Interest Debt Per Share0.00590.00625.4161
Slightly volatile
Debt To Assets0.04810.05060.3466
Slightly volatile
Days Of Payables Outstanding1.491.681.8275
Slightly volatile
Long Term Debt To Capitalization0.140.150.3242
Slightly volatile
Total Debt To Capitalization0.05270.05550.3795
Slightly volatile
Debt Equity Ratio0.05540.05830.767
Slightly volatile
Quick Ratio12.098.687110.6188
Very volatile
Net Income Per E B T0.81.00.9819
Slightly volatile
Cash Ratio1.721.81325.4324
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00111.0498
Slightly volatile
Debt Ratio0.04810.05060.3466
Slightly volatile
Gross Profit Margin0.560.630.6896
Slightly volatile

Lipocine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14 M14.7 M59.2 M
Slightly volatile
Enterprise Value9.5 M9.9 M41.6 M
Very volatile

Lipocine Fundamental Market Drivers

Cash And Short Term Investments22 M

Lipocine Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as revenue or net income, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue914.8 K813.2 K
Total Revenue-2.9 M-2.7 M
Cost Of Revenue10.2 M9.4 M
Stock Based Compensation To Revenue(0.23)(0.22)
Sales General And Administrative To Revenue(1.72)(1.63)
Research And Ddevelopement To Revenue(3.57)(3.39)
Revenue Per Share(0.54)(0.51)
Ebit Per Revenue 6.29  6.60 

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipocine Stock

  0.62VRAX Virax Biolabs GroupPairCorr
  0.59FENC Fennec PharmaceuticalsPairCorr
  0.52FATE Fate TherapeuticsPairCorr
  0.51VRCA Verrica PharmaceuticalsPairCorr
  0.51ELEV Elevation OncologyPairCorr
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Revenue Per Share
0.903
Quarterly Revenue Growth
137.519
Return On Assets
(0.23)
Return On Equity
(0.34)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.